Despite missing its primary endpoint, Equillium is pushing ahead with itolizumab citing its complete response by day 99.

Axsome Therapeutics AXSM announced that the phase III FOCUS study, which evaluated solriamfetol for the treatment of ...

Vertex Pharmaceuticals (VRTX) announced several updates on the company’s type 1 diabetes portfolio. Vertex has completed enrollment and dosing ...

Equillium’s phase 3 graft-versus-host disease (GVHD) trial has missed its primary endpoint and two key secondary objectives.

The FDA approved Kerendia in July 2021 for adults with chronic kidney disease associated with Type 2 diabetes to reduce the ...

Novo Nordisk has submitted a supplemental application to the FDA for Rybelsus 14 mg to lower cardiovascular risk in adults ...

A novel islet cell therapy delivered through a single infusion lowered HbA1c and eliminated severe hypoglycemia events for ...

CNS Pharmaceuticals said its Berubicin treatment for an aggressive and usually fatal brain cancer didn't show a statistically significant difference in overall survival during a clinical trial, ...

The stock has slightly recovered, with an expected close price of $0.48. Despite missing its primary endpoint, the company has said it plans to file for breakthrough therapy designation before the ...